Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
JP Morgan Launches US Dividend ETF

JP Morgan rolls out multi-cap US Dividend ETF.

HFC : 44.39 (-0.89%)
JDIV : 25.11 (unch)
DVY : 95.61 (-0.01%)
JNJ : 137.29 (-0.76%)
SDY : 93.59 (+0.05%)
DLR : 117.21 (-0.90%)
MCD : 169.05 (+0.45%)
NNN : 42.55 (-0.26%)
MSFT : 83.11 (-0.73%)
LMT : 314.87 (-0.65%)
T : 34.87 (+1.57%)
VIG : 98.13 (-0.31%)
PEP : 115.08 (-0.84%)
CME : 141.87 (-0.50%)
SKT : 24.40 (+1.08%)
DWDP : 70.60 (-0.93%)
J&J Seeks Darzalex's Label Expansion in First-Line Setting

Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

CELG : 105.16 (+0.63%)
JNJ : 137.29 (-0.76%)
AMGN : 169.96 (+0.07%)
BMY : 61.14 (-0.16%)
JP Morgan Launches US Dividend ETF

JP Morgan rolls out multi-cap US Dividend ETF.

HFC : 44.39 (-0.89%)
JDIV : 25.11 (unch)
DVY : 95.61 (-0.01%)
JNJ : 137.29 (-0.76%)
SDY : 93.59 (+0.05%)
DLR : 117.21 (-0.90%)
MCD : 169.05 (+0.45%)
NNN : 42.55 (-0.26%)
MSFT : 83.11 (-0.73%)
LMT : 314.87 (-0.65%)
T : 34.87 (+1.57%)
VIG : 98.13 (-0.31%)
PEP : 115.08 (-0.84%)
CME : 141.87 (-0.50%)
SKT : 24.40 (+1.08%)
DWDP : 70.60 (-0.93%)
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

JNJ : 137.29 (-0.76%)
GILD : 72.82 (+0.43%)
PFE : 35.43 (-0.31%)
GSK : 35.06 (+0.72%)
New Data Demonstrates >90% Year 1 Success Rate for Radiofrequency Ablation in Treating Patients with Atrial Fibrillation

Published data from the Journal of American College of Cardiology: Clinical Electrophysiology showcased at the 15th edition of Venice Arrhythmias 2017

JNJ : 137.29 (-0.76%)
Quality Dividend ETFs to Tackle Uncertainty

Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.

MSFT : 83.11 (-0.73%)
AAPL : 174.96 (+1.05%)
QDF : 43.36 (-0.12%)
WFC : 54.06 (-0.84%)
INTC : 44.65 (-0.65%)
JNJ : 137.29 (-0.76%)
DGRW : 39.82 (-0.10%)
SCHD : 49.20 (-0.22%)
HD : 172.06 (-0.46%)
BA : 265.15 (-0.69%)
Quality Dividend ETFs to Tackle Uncertainty

Consider these 3 dividend ETFs for your portfolio to fight growing market uncertainty.

MSFT : 83.11 (-0.73%)
AAPL : 174.96 (+1.05%)
QDF : 43.36 (-0.12%)
WFC : 54.06 (-0.84%)
INTC : 44.65 (-0.65%)
JNJ : 137.29 (-0.76%)
DGRW : 39.82 (-0.10%)
SCHD : 49.20 (-0.22%)
HD : 172.06 (-0.46%)
BA : 265.15 (-0.69%)
United Therapeutics PAH Drug's Exclusivity Period Extended

United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

JNJ : 137.29 (-0.76%)
LLY : 83.68 (+0.20%)
GILD : 72.82 (+0.43%)
UTHR : 125.41 (unch)
Risperdal Gynecomastia Lawsuit Headed for New Trial After Pennsylvania Superior Court Overturns Defense Verdict, Bernstein Liebhard LLP Reports

A Plaintiff who claims to have developed gynecomastia due to his use of Risperdal will get a new trial, after a three-judge panel of the Pennsylvania Superior Court reversed the only verdict favoring Johnson...

JNJ : 137.29 (-0.76%)
Global Intraocular Lenses Strategic Market 2016-2024 - Leading Players are Alcon, Bausch & Lomb, Johnson & Johnson Vision Care, Zeiss

The "Intraocular Lenses - Global Strategic Business Report" report has been added to Research and Markets' offering.

JNJ : 137.29 (-0.76%)
Johnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Citi 2017 Global Healthcare Conference on Thursday, Dec. 7, at Lotte New York Palace, NY. Joaquin Duato, Executive Vice President, Worldwide Chairman,...

JNJ : 137.29 (-0.76%)
Johnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference

NEW BRUNSWICK, N.J. , Nov. 20, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi 2017 Global Healthcare Conference on Thursday, Dec. 7 , at Lotte New York Palace,...

JNJ : 137.29 (-0.76%)
Johnson & Johnson Innovation Announces Winner of its Advancing the Safe Use of Healthcare Products QuickFire Challenge

Johnson & Johnson Innovation LLC today announced developers at CertaDose, Inc. have won its latest QuickFire Challenge: Advancing the Safe Use of Healthcare Products. The challenge called for potentially...

JNJ : 137.29 (-0.76%)
Legal-Bay Pre Settlement Funding Company Announces $247 Million Settlement For Faulty DePuy Pinnacle Hip Replacements

Legal-Bay LLC, The Pre Settlement Lawsuit Funding Company, reports today that a $247 million settlement was awarded to six plaintiffs who experienced numerous problems with their hip-replacement devices....

JNJ : 137.29 (-0.76%)
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with...

TBPH : 28.24 (-1.05%)
INVA : 13.42 (+0.07%)
JNJ : 137.29 (-0.76%)
GSK : 35.06 (+0.72%)
US Anticoagulation Therapy Market to 2022 - Major Players are C. H. Boehringer Sohn, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Daiichi Sankyo and Portola Pharmaceuticals

The "US Anticoagulation Therapy Market - Forecast to 2022" report has been added to Research and Markets' offering.

JNJ : 137.29 (-0.76%)
PTLA : 51.27 (+0.93%)
BMY : 61.14 (-0.16%)
Hip Replacement Lawsuit News: DePuy Pinnacle Plaintiffs Awarded $247 Million At Conclusion of 4th Federal Bellwether Trial, Bernstein Liebhard LLP Reports

Johnson & Johnson and its DePuy Orthopaedics subsidiary have been ordered to pay $247 million to six plaintiffs who experienced the premature failure of a metal-on-metal version of the companies' Pinnacle...

JNJ : 137.29 (-0.76%)
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case

A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective metal-on-metal hip implants made by Johnson & Johnson...

JNJ : 137.29 (-0.76%)
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case

DALLAS , Nov. 16, 2017 /PRNewswire/ -- A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective...

JNJ : 137.29 (-0.76%)
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

AZN : 33.83 (+0.30%)
JNJ : 137.29 (-0.76%)
LLY : 83.68 (+0.20%)
PFE : 35.43 (-0.31%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 NASDAQ 100 stocks with the highest Weighted Alpha and the most consistent price appreciation.
HLG -0.70 , ESIO +0.01 , SQ +0.75 , ZAGG -0.65 , OSTK +0.60
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.11%) this morning are up +0.03% and European stocks are up +0.12% as strength in energy stocks lifts the overall market. Energy stocks caught a bid after Jan WTI crude oil ( CLF18 +1.72%)... Read More

Chart of the Day

Chart of the Day

Fanhau (FANH) is the Barchart Chart of the Day.  The Chinese insurance broker has a Trend Spotter buy signal, a Weighted Alpha of 216.85+ and gained 162.34% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended the pre-Thanksgiving session with most contracts steady to a penny higher. They showed little reaction to last week’s record ethanol production (corn use >111 mbu for the week using a 2.84 gal/bu yield), as huge stocks and...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart